Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI
Clinical trial NCT07658105 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07658105
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-12
- Primary completion
- 2028-06-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.